Michael L Jones's most recent trade in Biocryst Pharmaceuticals Inc. was a trade of 8,500 Emp. Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 19, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals Inc. | Michael L. Jones | Exec. Director, Finance - PAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 8,500 | 8,500 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Michael L. Jones | Exec. Director, Finance - PAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 5,900 | 16,653 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Michael L. Jones | Exec. Director, Finance - PAO | Sale of securities on an exchange or to another person at price $ 10.90 per share. | 15 Dec 2022 | 445 | 10,753 (0%) | 0% | 10.9 | 4,851 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Michael L. Jones | Exec. Director, Finance - PAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 8,600 | 0 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Michael L. Jones | Exec. Director, Finance - PAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.42 per share. | 01 Dec 2022 | 8,600 | 19,798 (0%) | 0% | 1.4 | 12,212 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Michael L. Jones | Exec. Director, Finance - PAO | Sale of securities on an exchange or to another person at price $ 13.01 per share. | 01 Dec 2022 | 8,600 | 11,198 (0%) | 0% | 13.0 | 111,886 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Michael L. Jones | Exec. Director, Finance - PAO | Sale of securities on an exchange or to another person at price $ 17.20 per share. | 01 Mar 2022 | 2,300 | 11,198 (0%) | 0% | 17.2 | 39,560 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Michael L. Jones | Exec. Director, Finance - PAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 2,300 | 0 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Michael L. Jones | Exec. Director, Finance - PAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.73 per share. | 01 Mar 2022 | 2,300 | 13,498 (0%) | 0% | 4.7 | 10,879 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Michael L. Jones | Exec. Director, Finance - PAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 11,700 | 11,700 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Michael L. Jones | Exec. Director, Finance - PAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 5,850 | 11,198 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Michael L. Jones | Exec. Director, Finance - PAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2021 | 4,500 | 0 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Michael L. Jones | Exec. Director, Finance - PAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.51 per share. | 18 Mar 2021 | 4,500 | 5,348 (0%) | 0% | 3.5 | 15,795 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Michael L. Jones | Exec. Director, Finance - PAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2020 | 30,000 | 30,000 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Michael L. Jones | Exec. Director, Finance - PAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2020 | 5,000 | 5,000 | - | - | Emp. Stock Option (Right to Buy) |